Pro-Resolving Mediators in Acute Inflammation in Humans

• Status: Recruiting
• Trial end date: 2021-12-15
• Target enrollment: 0
• Participant gender: All

Summary

The investigators are undertaking a clinical blister model with or without dietary supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized pro-resolving mediators - endogenous lipids converted from omega-3 fatty acid precursors including those in Lovaza - on inflammation parameters and their resolution.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborator: National Institute of General Medical Sciences (NIGMS)

Criteria

Inclusion Criteria:

• Healthy adults

• Ages 18-64

Exclusion Criteria:

• Known acute or chronic infection

• Known acute or chronic disease of any kind

• Known allergy to fish or shellfish

• Use of any prescription medication

• Use of over-the-counter medication except multivitamins

• Use of dietary or herbal supplement except protein supplements

• Women that are pregnant, trying to become pregnant, or breastfeeding

• Any skin disease

• Known immunocompromise, HIV, or Diabetes mellitus

• History of cardiopulmonary disease

• History of upper extremity cellulitis

• Significant allergy of any kind

• Known bleeding diathesis

• History of keloid scar formation

• Forearm tattoo

• Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) during study or within 2 weeks prior to enrollment.